NOVARTIS N (NOT DU) stock market data APIs
€131.3634
2.11(1.6%)
as of March 18, 2026
Try our APIs with
free plan!
NOVARTIS N Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NOT.DU.
Prev. Close
131.3634
Open
133.4763
High
134.9993
Low
131.1607
52 wk Range
72.9751-139.5426
Market Cap
160 075 M
Dividends (Yield)
0.0487
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NOVARTIS N data using free add-ons & libraries
Get NOVARTIS N Fundamental Data
NOVARTIS N Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NOVARTIS N News
New
Novartis Places $3 Billion Bet On Early Cancer Drug
This article first appeared on GuruFocus. Novartis (NYSE:NVS) is leaning further into cancer treatments, agreeing to buy an experimental breast cancer drug from Synnovation Therapeutics in a deal wor...
Novartis to buy experimental breast cancer drug in up to $3 billion deal
FRANKFURT, March 20 (Reuters) - Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate for up to $3 billion from U.S. biotech firm Synnovation Therapeutics, adding a tar...
Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program
Synnovation will receive total cash consideration of up to $3 billion, consisting of $2 billion in upfront cash and up to $1 billion in development, regulatory, and commercial milestone payments WILM...
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Novartis Pharma AG Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
